Table 2 |
||||
|
Cox univariate and multivariate analysis of recurrence-free and breast cancer-specific survival according to HMGCoA-reductase expression in all, oestrogen receptor (ER) positive and ER-negative patients. |
||||
| Recurrence-free survival |
Breast cancer-specific survival |
|||
|
|
||||
| RR (95%CI) |
p value |
RR (95%CI) |
p value |
|
|
|
||||
| All patients |
Univariate |
Univariate |
||
| HMG-CoAR negative |
1.00 |
1.00 |
||
| HMG-CoAR positive |
0.57 (0.40 to 0.82) |
0.002 |
0.64 (0.91 to 1.03) |
0.07 |
| Multivariate |
Multivariate |
|||
| HMG-CoAR negative |
1.00 |
1.00 |
||
| HMG-CoAR positive |
0.60 (0.40 to 0.92) |
0.02 |
0.66 (0.39 to 1.11) |
0.12 |
|
|
||||
| ER positive |
Univariate |
Univariate |
||
| HMG-CoAR negative |
1.00 |
1.00 |
||
| HMG-CoAR positive |
0.46 (0.31 to 0.69) |
<0.001 |
0.59 (0.34 to 1.00) |
0.02 |
| ER negative |
||||
| HMG-CoAR negative |
1.00 |
1.00 |
||
| HMG-CoAR positive |
1.68 (0.70 to 4.03) |
0.25 |
2.47 (0.81 to 7.54) |
0.11 |
| Term of interaction* |
0.004* |
0.01* |
||
|
|
||||
| ER positive |
Multivariate |
Multivariate |
||
| HMG-CoAR negative |
1.00 |
1.00 |
||
| HMG-CoAR positive |
0.47 (0.30 to 0.73) |
0.001 |
0.67 (0.38 to 1.17) |
0.16 |
| ER negative |
||||
| HMG-CoAR negative |
1.00 |
1.00 |
||
| HMG-CoAR positive |
1.45(0.35 to 5.97) |
0.61 |
2.00 (0.37 to 10.93) |
0.42 |
| Term of interaction* |
0.01* |
0.11* |
||
|
|
||||
|
Multivariate analysis adjusted for Nottingham histological grade (I–II/III), age (continuous), nodal status(0/1), and tumour size (continuous). ER status (positive/negative, 10% cut-off), and human epidermal growth receptor 2 (HER2) immunohistochemistry 0 to 2 vs 3. * = Ŧ p value for term of interaction including ER (0/1), HMG-CoAR (0/1) and an interaction variable. |
||||
|
Borgquist et al. Breast Cancer Research 2008 10:R79 doi:10.1186/bcr2146 |
||||
